Article Text
PDF
Abstract
A previously healthy 27-year-old man was admitted to the acute neurology ward with events involving his face, throat and upper limb, which video telemetry later confirmed were refractory focal seizures. He also had progressive pyramidal features, dysarthria and ataxia. MR scans of the brain identified progressive bilateral basal ganglia abnormalities, consistent with Leigh syndrome. However, extensive laboratory and genetic panels did not give a unifying diagnosis. A skeletal muscle biopsy showed no histopathological abnormalities on routine stains. Sequencing of the entire mitochondrial genome in skeletal muscle identified a well-characterised pathogenic variant (m.10191T>C in MT-ND3; NC_012920.1) at 85% heteroplasmy in skeletal muscle. We discuss the clinical and molecular diagnosis of an adult presenting with Leigh syndrome, which is more commonly a paediatric presentation of mitochondrial disease, and how early recognition of a mitochondrial cause is important to support patient care.
- CLINICAL NEUROLOGY
- NEUROGENETICS
- MITOCHONDRIAL DISORDERS
- METABOLIC DISEASE
Data availability statement
No data are available. n/a.
Statistics from Altmetric.com
Data availability statement
No data are available. n/a.
Footnotes
Contributors TW-F, VM, NEF, RWT, YSN, AS, GSG and MEF involved in collating case, drafting and proof-reading submission. NEF, VL, DP, CVYH, SH, RWT, YSN, AS and GSG involved with expertise and specialist advice on mitochondrial disorders.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed by Patrick Chinnery, Cambridge, UK.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.
Read the full text or download the PDF:
Other content recommended for you
- A guide to diagnosis and treatment of Leigh syndrome
- Complex I deficiency: clinical features, biochemistry and molecular genetics
- Mutation screening of 75 candidate genes in 152 complex I deficiency cases identifies pathogenic variants in 16 genes including NDUFB9
- Prevalence of rare mitochondrial DNA mutations in mitochondrial disorders
- Recognition, investigation and management of mitochondrial disease
- Mutant NDUFS3 subunit of mitochondrial complex I causes Leigh syndrome
- Diagnosis of ‘possible’ mitochondrial disease: an existential crisis
- A frameshift mitochondrial complex I gene mutation in a patient with dystonia and cataracts: is the mutation pathogenic?
- Progressive myoclonic epilepsy as an adult-onset manifestation of Leigh syndrome due to m.14487T>C
- Dopamine transporter SPECT in patients with mitochondrial disorders